Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTO1681 for the Prevention and Treatment of CRS in CAR T-Cell Therapy
NCT05905328Phase 2Recruiting
- Sponsor
- CytoAgents
- Start
- Dec 2023
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of CTO1681 in cytokine release syndrome (CRS) (5 arms), sponsored by CytoAgents. Primary endpoint: Incidence of adverse events at 6 months. Started Dec 2023; status: recruiting.
02
Drugs
CTO1681
03
Conditions
cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT05905328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905328.